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Interferon  A lfa -2 a  and In te r le u k in -2  W ith  or W ith ou t  
Cisplatin  in M eta s ta t ic  M ela n o m a : A R an d om ized  T r ia l  
of the E u rop ean  O r g a n iza t io n  for R esearch  and  
Treatm ent of C ancer M e la n o m a  C oop erative  G roup
By Ulrich Keilholz, Swan Hoo Goey, Cornelis J.A. Punt, Thomas M. Proebstle, Ralph Salzmann,
Carmen Scheibenbogen, Dirk Schadendorf, Danielle Liénard, Alexander Enk, Reinhard Dummer, Birgit Hantich,
Anne-Marie Geueke, and Alexander M .M . Eggermont
Purpose: The combination of interferon alfa-2a 
(IFNa) and high-dose interleukin-2 (IL-2) is active in met­
astatic melanoma. The addition of cisplatin (CDDP) has 
resulted in response rates greater than 50%. This study 
was performed to determine whether the addition of 
CDDP to a cytokine treatment regimen with IFNa and 
high-dose IL-2 influences survival of patients with meta­
static melanoma.
Patients and Methods: Patients with advanced meta- 
static melanoma were randomly assigned to receive 
treatment with IFNa; 10 x 10 6 U/m2 subcutaneously on 
days 1 through 5 and a high-dose intravenous decre­
scendo regimen of IL-2 on days 3 through 8 (18 mlU/ 
m2/6 hours, 18 mlU/m2/12 hours, 18 mlU/m2/24 hours, 
and 4.5 mlU/m2/24 hours x 3) without (arm A) or with 
(arm D) CDDP 100 mg/m2 on day 1. Treatment cycles 
were repeated every 28 days to a maximum of four cy­
cles.
THERE IS NO STANDARD treatment for advanced metastatic melanoma. With dacarbazine as a single 
agent, an approximately 15% objective remission rate 
can be achieved with a duration of 4 to 6 months.1,2 
Combination chemotherapy may increase response rates 
up to 40%, but without an impact on survival.1,3 The 
activity of interleukin-2 (IL-2) has been extensively tested 
during the past decade.4'7 Up to 20% of patients have 
experienced tumor responses with IL-2 administered in 
high-dose regimens, and some long-term survivors have 
been reported in most trials. Interferon alfa (IFNa) is also 
an active agent in melanoma.8 Twenty percent to 40% of 
patients achieve objective remissions with the combina­
tion of IL-2 and IFNa:.9*12 
The addition of dacarbazine to IL-2 in phase II trials 
resulted in response rates similar to those achieved with 
IL-2 treatment alone.13'15 More recently, several single- 
institution trials have investigated the combination of var­
ious cytotoxic agents with IFNa and high-dose IL-216-18 
and a multicenter phase II trial that combined cisplatin 
(CDDP), dacarbazine, and tamoxifen with high-dose IL-
2 has been performed by the Cytokine Working Group.19 
Sixteen percent to 56% objective response rates were 
achieved with these combinations that involved two to 
six agents. When the three agents CDDP, IFNa, and high- 
dose IL-2 were part of the treatment regimen, the response
Results: One hundred thirty-eight patients with ad­
vanced metastatic melanoma, of whom 87% had visceral 
metastases, were accrued for the trial. Both regimens 
were feasible in a multicenter setting. The objective re­
sponse rate was 18% without and 33% with CDDP (P = 
.04). The progression-free survival was 53 days without 
and 92 days with CDDP (P = .02, Wilcoxon; P = .09, log- 
rank). There was no statistically significant difference in 
survival between treatment arms, with a median overall 
survival duration for all patients of 9 months.
Conclusion: The addition of CDDP to cytokine treat- 
ment with IFNa and IL-2 does not influence survival of 
patients with advanced metastatic melanoma, despite a 
significant increase in response rate and progression- 
free survival.
J  Clin Oncol 15:2579-2588. © 1997 by American So­
ciety of Clinical Oncology.
rates were greater than 50% in all phase II trials reported. 
Concurrent administration of cytokines and cytotoxic 
agents was suggested to be more efficacious than alternat­
ing administration, unless chemotherapy immediately 
preceded cytokine treatment.18 However, it remains un­
certain whether these increased response rates, which
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were sometimes achieved with considerable toxicity, 
translate into a survival benefit.
The toxicity of high-dose intravenous administration 
of IL-2 plus IFNa is of major concern and has for a long 
time prohibited larger multicenter trials.20,21 However, 
when IL-2 is not administered at a continuous dose rate, 
but according to a decrescendo regimen, adverse effects 
may be significantly reduced without apparently compro­
mising efficacy.11
The addition of CDDP to IFNa and high-dose IL-2 
was found feasible for a multicenter setting in a phase II 
trial22 Furthermore, CDDP did not impair the induction 
of secondary cytokines and serum CD25 by IL-2, which 
suggests that this cytotoxic drug does not impair the im­
munologic effects mediated by IL-2. Previously, it has 
been shown that CDDP does not abolish the IL-2-medi­
ated cellular responses (eg, lymphocytosis and lympho- 
kine-activated killer [LAK] activity) in the peripheral 
blood.23 There is even evidence that CDDP may to some 
extent enhance endogenous LAK activity.24
We report here on a randomized multicenter trial per­
formed within the European Organization for Research 
and Treatment of Cancer (EORTC) Melanoma Coopera­
tive Group that investigated whether the addition of 
CDDP to a combination of IFNa and IL-2 significantly 
influences survival of patients with advanced metastatic 
melanoma. The trial was designed to detect a significant 
doubling of the median survival time by adding CDDP. 
Secondary objectives of the trial included response rate 
and time to treatment failure.
PATIENTS AND METHODS
The inclusion criteria for this trial were metastatic melanoma with 
measurable disease parameters, which could not be controlled by 
surgery, and a Karnofsky performance status of at least 60%. Exclu­
sion criteria were the presence of brain métastasés on brain computed 
tomographic (CT) scan or magnetic resonance imaging (MRI); prior 
therapy with CDDP; chemotherapy within 3 months of protocol 
treatment; symptomatic cardiac, pulmonary, renal, liver, or thyroid 
disease; autoimmune diseases; corticosteroid treatment; and signifi­
cant bone marrow dysfunction. The protocol was approved by the 
institutional review committees of all participating hospitals and 
informed consent was obtained from all patients before randomiza­
tion. Only centers with experience in the administration of high- 
dose IL-2 ( «  20% of hospitals that participate in clinical trials of 
the EORTC Melanoma Cooperative Group) participated in this trial.
Treatment Plan
Patients randomized to arm A received IFNa-2a (Roferon; Roche, 
Basel, Switzerland) 10 X  106 U/mVd subcutaneously on days 1 
through 5, IL-2 (Proleukin; Chiron, Amsterdam, the Netherlands) 
was given as continuous intravenous infusion in a decrescendo 
schedule starting on day 3 with 18 mIU/m2 every 6 hours followed
by 18 mIU/m2 every 12 hours» 18 mIU/m2 every 24 hours, and a 
maintenance dose of 4.5 mIU/m2 every 24 hours for 72 hours. Arm 
B consisted of the same regimen of IFNa and IL-2 with the addition 
of CDDP 100 mg/m2 intravenously as a single dose on day 1. Cycles 
were repeated every 4 weeks for a maximum of four cycles in the 
absence of disease progression.
In patients who had completed at least one treatment cycle, tumor 
assessment was performed after the second and the fourth treatment 
cycle according to standard World Health Organization (WHO) crite­
ria.25 In addition to the WHO criteria, a minor response category 
was defined as a 25% to 50% reduction in the sum of the product 
of the two largest perpendicular diameters of all measurable lesions 
for the purpose of decisions on further treatment after the second 
cycle. For analysis of objective responses, minor response (MR) has 
been classified as stable disease (SD) in agreement with WHO crite­
ria, Patients who responded to two cycles of treatment with a MR 
or better received two additional treatment cycles. Patients with SD 
or progressive disease after two treatment cycles were monitored 
without further protocol treatment.
In case of any grade 4 toxicity, protocol treatment was discon­
tinued, except in case of grade 4 hematologic toxicities if they had 
resolved at the time of re-treatment. In case of grade 3 ototoxicity 
or renal toxicity in patients randomized to the CDDP arm, CDDP 
was omitted in subsequent treatment cycles. For all other grade III 
toxicities (except fever, nausea/vomiting, and diarrhea, which were 
treated symptomatically), treatment was withheld until the toxicity 
improved to grade 1. In case of the following grade 3 toxicities 
during the IL-2 infusion, the infusion was interrupted and the toxicity 
reassessed every 2 hours, until resolution to at least grade 1: hypoten­
sion not responding to concomitant therapy, cardiac arrhythmia, sus­
picion of myocardial ischemia, agitation or persistent confusion, 
elevation of bilirubin level to greater than 60 ¿¿mol/L, bacterial sep­
sis, or dyspnea at rest. In case of the following toxicities, subsequent 
IL-2 was administered at 50% dose: increase in serum creatinine 
concentration to greater than 265 ¿¿mol/L or grade IV neurotoxicity 
in the previous cycle,
After completion of study treatment, patients were monitored ev- 
eiy 2 months during the first 6 months and every 3 months thereafter. 
Surgical removal of residual lesions aiming at resection of all re­
maining metastases was considered in all patients who achieved at 
least an MR with protocol treatment.
Statistical Evaluation
The median survival duration in the arm without CDDP was ex­
pected to be 9 to 12 months. Assuming an underlying exponential 
distribution of survival, a median survival time of 12 months corre­
sponds with a 2-year survival rate of approximately 25%, Doubling 
the median survival duration from 12 months in the arm without 
CDDP to 24 months in the arm with CDDP would correspond with 
a doubling of the 2-year survival rate from 25% to 50%. Using the 
log-rank test with a one-sided a error of 5% and 0  error of 10%, 2 
X  62 patients would allow the detection of a significant doubling 
of the median survival time. The number of patients randomized 
was 138 to safeguard for up to 10% of possible noneligible patients 
and patients not available for follow-up evaluation.
Before randomization, patients were stratified according to treat­
ment center and extent of disease to assure equal assignment of risk 
groups to the two treatment arms. Patients with a serum lactate 
dehydrogenase (LDH) level within the institutional normal limits 
and a cross-sectional surface area of all measurable metastases of
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Table 1. Patient Characteristics
Characteristic
%  of Patients
All Patients
(N = 137)
Arm A; 
Without CDDP 
(r> = 71 )
Arm B: 
With CDDP 
(n = 66)
Karnofsky performance status [ % )
oCSAl 82 82 82
<  90 18 18 18
Site of disease
Cutaneous, subcutaneous only 2 2 2
Lymph nodes with or without
cutaneous, subcutaneous 11 12 9
Visceral 87 86 88
Extent of disease
1 organ site 37 41 33
2 organ sites 38 39 37
> 2 organ sites 25 20 30
<  30 cm2 75 77 72
>  30 cm2 25 23 28
Normal LDH 56 58 53
Elevated LDH 44 42 47
Pretreatment
No systemic pretreatment 78 77 80
Cytotoxic agents 11 10 11
Adjuvant IFNcv 15 12 18
Adjuvant IL-2 7 5 9
NOTE. None of the differences was statistically significant.
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Table 2. Toxicity of Treatment (worst toxicity of any cycle)
Toxicity
%  of Patients 
in Arm A: 
Without CDDP 
(grade)
3 4
% of Patients in 
Arm B: 
With CDDP
(grade)
3 4 P
Fever 15 4 .07
Hematologic
Anemia 4 13 .02
Leukopenia 2 25 2 <  .01
Thrombocytopenia 8 23 15 <  .01
Renal 0 13 2 <  .01
Liver 0 4 NS
Nausea ó 35 <  .01
Vomiting 4 32 <  .01
Diarrhea 12 14 NS
Anorexia 25 40 .02
Cto 4 9 NS
Alopecìa 100 91 9 <  .01
Pain 8 ó NS
Fatigue 12 15 NS
Cardiac 0 1 NS
Mental change 0 4 NS
Neurologic 0 1 NS
NOTE, Subjective hearing loss was reported by patients who received 
CDDP. However, the frequency of ototoxicity cannot be accurately as­
sessed, since no hearing tests were performed.
Abbreviation: NS, not significant (P >  ,05).
less than 30 cm2 were entered into stratum I, and patients with a 
serum LDH level above the institutional normal limits and/or a cross- 
sectional surface of all measurable metastases greater than 30 cm2 
were entered in stratum II.
Fisher’s exact test was used to compare response rates and toxici- 
ties between treatment arms. Survival curves were computed ac­
cording to the Kaplan-Meier method and compared using the Wil- 
coxon and the log-rank tests.
RESULTS
A total of 138 patients was accrued for the trial and 
randomized between April 1993 and May 1995. One hun­
dred thirty-seven patients met the inclusion criteria. Four 
patients from one institution could not be analyzed. The 
treatment had reportedly been administered to all four 
patients according to protocol without major toxicity, but 
unfortunately no follow-up data are available, which re­
duces the total number of assessable patients to 133. Pa­
tient characteristics are listed in Table 1. Most patients 
had a Karnofsky performance status of at least 90%. In 
both patient strata, more than 85% of patients had metas­
tases that involved visceral organs. Nine patients had re­
ceived prior chemotherapy for metastatic disease (always 
dacarbazine), while the remaining 93% of patients had 
not received any prior systemic treatment for metastatic 
melanoma.
Toxicity
A total of 301 treatment cycles were administered (147 
without and 154 with CDDP) and all 133 patients were 
assessable for toxicity of treatment. The administration 
of cytokines (arm A) was associated with known side 
effects as a flu-like syndrome, capillary leak syndrome, 
fluid retention, hypotension, gastrointestinal symptoms 
(nausea and diarrhea), CNS symptoms (lethargy, depres­
sion, and agitation), and abnormal kidney and liver func­
tion tests (Table 2). Grade III toxicities, mostly fever, 
occurred in 58% of patients; grade IV toxicities were not 
observed. The addition of CDDP (arm B) resulted in an 
increase of variety of toxicities, and 65% of patients in 
arm B experienced grade III toxicities and 20% grade IV 
toxicities, mainly thrombocytopenia and nausea. CDDP 
was associated with significantly increased renal toxicity. 
Three patients (two with and one without CDDP) with 
large liver metastases that replaced more than one third 
of the liver tissue developed significant hepatic toxicity 
with hyperbilirubinemia and abnormal coagulation tests 
for several days. All side effects could be managed by 
standard care and disappeared within a few days of treat­
ment completion, except for peripheral neurotoxicity and
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elevated serum creatinine concentration due to CDDP in 
some patients.
In 91% of treatment cycles, the planned dose of all 
study drugs was administered; treatment had to be modi­
fied in only 9% of cycles. Treatment modifications con­
sisted mostly (7% of cycles) of transient interruption of 
the IL-2 infusion because of fatigue, vomiting, diarrhea, 
bowel obstruction (in a patient with a large bowel metas­
tasis), cardiac arrhythmia, or hypotension. CDDP was 
omitted after the first cycle in a total of seven patients. 
In three patients, CDDP was omitted after the first cycle, 
in one patient after the second cycle, and in three patients 
after the third cycle for reasons of neurotoxicity (three 
patients), nausea (two patients), and nephrotoxicity (two 
patients). The dose of CDDP was reduced in one addi­
tional patient because of liver toxicity. Hearing loss was 
also noted in conjunction with CDDP; however, the fre­
quency cannot be accurately assessed, since no routine 
hearing tests were performed prospectively. In conclu­
sion, acute toxicity was considerable, as expected, but 
manageable, and no major long-term toxicities occurred.
One patient who did not fulfill the inclusion criteria 
because of symptomatic chronic obstructive lung disease 
and stable angina pectoris was randomized and received 
one cycle of protocol treatment that included CDDP. On 
day 6 of treatment, he developed pulmonary infiltrates 
with subsequent septicemia and he died of disseminated 
intravascular coagulopathy 3 days after discontinuation 
of IL-2.
Autoimmune phenomena were noted in six patients. 
One patient developed hyperthyroidism after the third 
treatment cycle and five patients developed arthritic 
changes (n = 2) or arthralgias (n = 3) of large joints 
following the second or third treatment cycle. No overt 
vitiligo was observed. Less pronounced vitiligo may have 
been overlooked, because no systematic screening for 
vitiligo was implemented in the study.
Response to Treatment
A total of 126 patients received at least one complete 
cycle of treatment and were assessable for response. Eight 
patients were not assessable for response because of the 
following reasons: four patients (two from arm A and 
two from arm B) refused further treatment and follow- 
up examinations after one treatment cycle in the absence 
of persisting toxicity or overt disease progression; thus 
intention-to-treat analysis is not affected or different from 
analysis by protocol One patient died suddenly of un­
known reason at home 2 weeks after completion of two 
treatment cycles in absence of overt disease progression.
Table 3. Response to Treatment
Response 1F Na/JL-2 IFNa/IL-2/CDDP
No. of patients 66 60
CR 4 3
PR 8 17 P = .04
SD 12 13 {CR/PR VSD/PD)
PD 42 27
% OR 18 33
95% a 9.8-29.6 21.7-46.7
Stratum 1
No. of patients 35 26
CR 2 1
PR 6 9 1!
CL.
SD 7 8 (CR/PR V SD/PD)
PD 20 8
% OR 23 38
95% Cl 10.4-40.1 20.2-59.4
Stratum II
No. of patients 31 34
CR 2 2
PR 2 8 P = .09
SD 5 5 (CR/PR V SD/PD)
PD 22 19
% OR 13 29
95% Cl 3.6-29.8 15.1-47.5
Abbrevia fions; OR, objective remissions; Cl, Pearson-Clopper confidence 
interval; CR, complete response; PR, partial response; SD, stable disease; 
PD, progressive disease.
A relationship of the sudden death to the protocol treat­
ment could not be established. One patient with a history 
of peptic ulcers developed bleeding from a peptic ulcer 
on day 1 of the first cycle of treatment that coincided 
with (but was not related to) the first administration of 
IFNa; protocol treatment was not resumed. Two patients 
received less than 24 hours of IL-2 infusion because of 
transient grade III toxicities (bowel obstruction and car­
diac arrhythmia, respectively), which led to treatment dis­
continuation.
Eighteen percent of patients (23% in stratum I and 13% 
in stratum II) achieved objective remissions with cytokine 
treatment alone, 18% had SD, and 64% had disease pro­
gression (Table 3). The addition of CDDP significantly 
(J° = .04) increased the objective response rate to 33% 
(38% in stratum I and 29% in stratum II); 22% of patients 
had SD and 45% progressed. Responses in both treat­
ment arms occurred at all organ sites, as summarized in 
Table 4.
Sixteen patients (nine without CDDP and seven with 
CDDP) underwent surgical resection of residual lesions, 
which resulted in a clinical complete remission (CR) in
IFNa/lL-2 ±  CDDP IN MELANOMA 2583
Table 4. Characteristics of Responders
Characteristic
lFNa/IL-2 
(n = 12)
IFNa/IL-2/CDDP 
(n = 20)
Karnofsky performance score
Range 80-100 60-100
Median 100 95
Sites of response (n)
Lung 4 10
Lymph nodes 3 6
Liver 4 4
Soft tissue 2 3
Skin/subcutaneous 2 2
Adrenal 2
Spleen 3
Bone r
*PR of extraosseous mass with evidence of bone recalcification.
seven patients (two without CDDP and five with CDDP). 
Residual lesions visible on CT scan were resected in two 
additional patients, but no remaining tumor cells were 
found on histology; therefore, these two patients were 
reclassified as having achieved CR by protocol treatment. 
Thus, 14 patients (11%) were free of macroscopic disease 
after treatment without (n = 7) or with (n =  7) second- 
line surgery (Table 5).
The median duration of objective responses without 
further medical treatment was 17 months without CDDP 
and 6 months with CDDP (P = .057, log-rank test; Fig
1 A). Immediate treatment failures with overt disease pro­
gression after one treatment cycle occurred in 23% of
patients without CDDP (14% in stratum I and 32% in 
stratum II) and in 17% patients with CDDP (8% in stra­
tum I and 24% in stratum II). The median time to treat­
ment failure of all patients was 53 days without CDDP 
and 92 days with CDDP (P = .02, Wilcoxon test; Fig 
IB). However, the curves merge at 9 months and there 
is no significant difference in time to progression between 
the two treatment arms using the log-rank test (P = .09). 
If the progression-free survival is calculated according 
to stratum, there is also a doubling in median time to 
progression in both strata and the curves merge at 10 and 
8 months, respectively (Fig 1C and D).
Survival
One patient was lost to follow-up evaluation, which 
left 132 patients assessable for survival analysis (Fig 2). 
The median survival duration is 9 months and there is no 
difference in survival between both treatment arms. The 
median survival duration of stratum I is 11 months (Fig 
3) and the median survival duration of stratum II is 7 
months (P =  .004, log-rank test). Comparative analyses 
within both patient strata are descriptive, because the pa­
tient number per stratum is limited. There is no apparent 
difference in survival between both treatments arms 
within either stratum. Only in stratum II is there a hint 
toward a longer survival rate after 12 months with CDDP, 
but this is not statistically significant.
Sixteen patients are still alive with a median follow- 
up time greater than 2 years, nine treated with cytokines
Table 5. Characteristics of 14 Patients Rendered Free of Visible Disease by Protocol Treatment With or Without Second-Line Surgery
Patient
No. Sites of Melastases
Prelreatment 
Serum LDH + / -  CDDP
Response to 
Treatment
Second-Lîne
Surgery
Time lo Relapse 
(months)
Sites of 
Relapse
Overall Survival 
(months)
13 Mediastinal 
Pancreas, liver
elev + CR NA NA CCR 38 +
44 Liver elev — SD Liver 4 Liver 10
48 Lung n — CR NA NA CCR 35+
58 Lung, In n + PR Hilar In 4 In, subcut, 11
60 Uterus, ascites n + PR Uterus 3 Skin, bone 11
66 Skin, In, spleen 
Liver, pancreas
n + PR Liver 10 Skin, In 
Adrenal
15
75 Spleen, In n + PR Spleen NA CCR 31 +
77 Skin, subcutaneous n + CR NA 5 Brain 7
81 Liver, In n — PR Liver, In NA CCR 25+
83 In, spleen n + PR In 4 Brain 12
88 Liver n — CR NA NA CCR 24+
89 Liver, lung, In elev -1- CR* NA NA CCR 27+
127 Lung n — CR* NA NA CCR 23 +
135 Lung n — CR NA NA CCR 22+
Abbreviations: In, lymph nodes; elev, elevated; n, within normal limits; NA, not applicable; CCR, continuous CR; NED, no evidence of disease, 
“ Residual lesions were suspected after 4 treatment cycles on CT scan, which on histology proved to be scar tissue in patients no. 89 and 127.
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Fig 1. (A) Duration of overall 
response according to treatment 
arm. Time to treatment failure 
according to (B) treatment arm 
and (C) stratum 1 or (D) stratum 2.
o 6 12 18 24 30 36 months
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Fig 1. (cont'd}.
o 6 1 2 18 24 30 36 months
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Fig 2. Survival of all patients 
according to treatment arm. Min­
imum follow-up time of surviving 
patients, 22 months.
Fig 3. Survival according to 
stratum and treatment arm. Stra­
tum I, n = 69 (— , normal pre­
treatment LDH and a cross-sec­
tional surface of all measurable 
métastasés <  30 cm2); stratum II, 
n =  64 (---, elevated pretreat­
ment serum-LDH and /o r a cross- 
sectional surface of all measur­
able métastasés >  30 cm2).
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alone and seven with CDDP. Nine patients were in the 
favorable stratum I (six treated without CDDP and three 
with CDDP) and seven patients in stratum II (three with­
out CDDP and four with CDDP). Of the surviving pa­
tients, eight (five without and three with CDDP) are still 
without evidence of disease recurrence between 22 and 
38 months postrandomization (Table 5), including six of 
seven compete responders by protocol treatment and two 
of seven surgical complete responders. The patient with 
relapse after CR by protocol treatment and one patient 
with a surgical CR developed brain metastases as the only 
site of relapse.
DISCUSSION
The results of phase II trials have suggested that a 
high response rate can be achieved in patients with 
advanced melanoma with chemoimmunotherapy that 
includes IL-2, IFNa, and CDDP.16"19,25 This trial con­
firms that the addition of CDDP significantly increases 
the response rate over cytokine treatment alone. How­
ever, the response rates in both treatment arms were 
lower as compared with phase II trials. This may be 
explained by differences in patient cohorts, since in 
contrast to most of the phase II trials with metastases 
confined to extravisceral sites in half of the patients, 
87% of patients in this trial had visceral metastases, 
which was associated with lower response rate to IFNa;/ 
IL-2 treatment in phase II trials.27
The addition of CDDP also decreased the rate of early 
treatment failures and increased the median progression- 
free survival in both patient strata. However, the duration 
of responses in arm B, with a median of 6 months, was 
much shorter than the median of 17 months with cytokine 
treatment alone, and the percentage of patients without 
progression beyond 1 year after randomization was not 
influenced by CDDP. Furthermore, the CR rate of was 
not improved by CDDP. Therefore, the improvement in 
response rate by the addition of CDDP did not translate 
into prolonged survival, except for a small hint in the 
more advanced disease stratum (stratum 2). This is in 
accordance with the observation that most partial re­
sponses after chemotherapy alone last for only a few 
months.1'3 Efforts to maintain partial responses by addi­
tional treatment do not seem feasible given the toxicity 
of the current regimen. It is conceivable that the addition 
of CDDP to immunotherapy only induced an additional 
number of short-lived responses, without influence on 
survival. An alternative explanation is that CDDP may 
compromise the biologic agents efficacy and thereby re­
duce the quality of some responses. Furthermore, resec­
tion of residual lesions may have had a small impact on 
long-term analysis,
CRs achieved by protocol treatment proved to be rather 
durable. Strategies to improve the number of CRs may 
therefore improve survival. The addition of CDDP alone 
did not result in an increase of the number of CRs. One 
could conceive that the CDDP dose-intensity of 100 mg/ 
m2/4 weeks has not been sufficient, arguing for intensi­
fying the chemotherapy regimen, but intensification of 
CDDP is prohibited by toxicity and may compromise 
cytokine-mediated effects.
The surgical resection of residual tumor lesions is an­
other approach to achieve CRs. In most instances, the 
initial site of recurrence after cytokine-induced regression 
of melanoma is from remaining metastases or from lymph 
nodes draining previous metastases.28 The duration of par­
tial remissions converted into CRs by surgery was similar 
to the duration of cytokine-induced CRs in a series of 
selected patients.28 For this trial, we prospectively adopted 
a policy of resecting residual lesions in an attempt to 
achieve better local control. An attempt to resect residual 
lesions was made in 15 patients and a total of seven could 
be rendered free of disease by removal of residual lesions 
after protocol treatment. However, only two of these sur­
gical CRs have been durable. Four of the patients with 
surgical CR, including three patients who received CDDP 
and one patient with SD after cytokine treatment, relapsed 
after a few months, and one patient developed brain me­
tastases as the only site of relapse. Based on the observa­
tions described previously, as well as in this trial, second- 
line surgery could perhaps be beneficial in selected cases, 
but cannot be generally recommended.
Twenty percent of patients from the more favorable 
stratum I are still alive with a median follow-up duration 
of 2 years, and there is a suggestion of a plateau in the 
Kaplan-Meier plot. This corresponds to the results of 
phase II trials of IL-2-based treatment in metastatic mela­
noma, in which always a proportion of long-term survi­
vors have been observed. This is in contrast to trials of 
chemotherapy or IFNs, in which the 2-year survival rate 
is less than 10% and the 5-year survival rate is approxi­
mately 2%;29,30 Current randomized trials within the 
EORTC Melanoma Cooperative Group and at the Na­
tional Cancer Institute are investigating prospectively 
whether the addition of high-dose IL-2 to treatment regi­
mens with IFNa and chemotherapy influences survival 
in patients with advanced melanoma.
The stratification procedure of this trial was based on 
limited single-institution experience, where serum LDH 
and tumor load were found to be the most significant
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independent prognostic factors for survival in a cohort of 
patients treated with IFNct and IL-227 and on retrospective 
analyses of chemotherapy and IFN trials.31 With this trial, 
we prospectively confirm the importance of these prog­
nostic factors for response and survival, which could be 
useful for stratification in future randomized trials, which 
are needed to establish whether chemoimmunotherapy 
combinations provide a meaningful benefit to patients
with advanced melanoma as compared with single-agent 
chemotherapy.
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